LB Form 4: Valerie Chase Receives 3,895 RSUs Vesting July 1, 2026
Rhea-AI Filing Summary
LandBridge Company LLC director Valerie Chase was granted 3,895 restricted stock units (Class A shares) on 08/27/2025 under the company’s Long-Term Incentive Plan. The RSUs vest on July 1, 2026, generally conditioned on continued service on the board through the vesting date. The filing reports 14,173 Class A shares beneficially owned by the reporting person after the grant. The Form 4 was filed as a single reporting-person filing and was signed by an attorney-in-fact on 08/28/2025. The grant appears recorded at a price of $0 in the Form 4 table.
Positive
- Director equity alignment: Grant of 3,895 RSUs aligns the reporting person’s interests with shareholders.
- Clear vesting schedule: RSUs vest on July 1, 2026, providing a defined retention incentive.
- Increased reported ownership: Beneficial ownership rises to 14,173 Class A shares after the grant.
Negative
- None.
Insights
TL;DR: A board-aligned, service-conditioned equity grant increases insider stake and ties compensation to continued service through mid-2026.
The grant of 3,895 RSUs to a director under the long-term incentive plan is a routine governance practice to align director interests with shareholders. Vesting is tied to continued board service until July 1, 2026, which is a common retention mechanism for non-employee directors. The post-grant beneficial ownership of 14,173 Class A shares signals a meaningful, though unspecified, ownership position relative to total outstanding shares (total outstanding not provided). No additional governance actions, departures, or related-party transactions are disclosed in this filing.
TL;DR: This is a standard insider equity award with limited immediate market impact absent further material company information.
From a securities perspective, the Form 4 records a non-derivative grant of RSUs vested on a future date, reported at $0 price, increasing reported beneficial ownership to 14,173 shares. The filing does not disclose exercise, sale, or hedging activity, and the grant’s absolute size relative to company capitalization is not included, limiting assessment of dilutive or market impact. The filing is informational and routine unless supplemented by material corporate disclosures.